SCHEMBL5280702

SCHEMBL5280702

O=S(=O)(Nc1ccc(F)c(F)c1)c1ccc(Nc2ccc(F)c(F)c2)c2nonc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.46
POLB P06746 1/20 0.46
SLC22A12 Q96S37 2/20 0.45
RORA P35398 1/20 0.43
RORC P51449 1/20 0.43
NR1H2 P55055 1/20 0.43
EPAS1 Q99814 2/20 0.40
ARNT P27540 1/20 0.40
PFKFB3 Q16875 1/20 0.39
SOS1 Q07889 1/20 0.39
MEN1 O00255 4/20 0.39
MAPT P10636 2/20 0.39
PSMD14 O00487 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GFER P55789 2/20 0.38
HSPD1 P10809 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN5 P54829 1/20 0.38
HSPE1 P61604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5277982 0.84 EPAS1 (0.51) KMT2APOLBEPAS1ARNTPFKFB3
SCHEMBL5299664 0.84 RORA (0.61) KMT2APOLBSLC22A12RORARORC
SCHEMBL6390668 0.79 KMT2A (0.68) KMT2APOLBSLC22A12MEN1MAPT
SCHEMBL5280376 0.76 POLB (0.55) KMT2APOLBSOS1MEN1MAPT
SCHEMBL5295964 0.74 POLB (0.50) KMT2APOLBSLC22A12MEN1MAPT
SCHEMBL5243227 0.74 KMT2A (0.56) KMT2APOLBRORARORCNR1H2
SCHEMBL5282149 0.72 BRD4 (0.52) KMT2APOLBMEN1MAPTRXFP1
SCHEMBL6392109 0.72 ALDH1A1 (0.53) KMT2ARORARORCNR1H2MEN1
SCHEMBL5278920 0.70 POLB (0.57) KMT2APOLBMEN1MAPTRXFP1
SCHEMBL8268581 0.69 EPAS1 (0.42) KMT2APOLBEPAS1ARNTPFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885POLB 2997/4885SLC22A12 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.